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Received 18 April 2008; received in revised form 14 August 2008; accepted 23 August 2008Abstract Human embryonic stem cells (hESCs) are pluripotent cells that can differentiate into neural cell lineages.
These neural populations are usually heterogeneous and can contain undifferentiated pluripotent cells that are capable of
producing teratomas in cell grafts. The characterization of surface protein profiles of hESCs and their neural derivatives is
important to determine the specific markers that can be used to exclude undifferentiated cells from neural populations.
In this study, we analyzed the cluster of differentiation (CD) marker expression profiles of seven undifferentiated hESC
lines using flow-cytometric analysis and compared their profiles to those of neural derivatives. Stem cell and progenitor
marker CD133 and epithelial adhesion molecule marker CD326 were more highly expressed in undifferentiated hESCs,
whereas neural marker CD56 (NCAM) and neural precursor marker (chemokine receptor) CD184 were more highly
expressed in hESC-derived neural cells. CD326 expression levels were consistently higher in all nondifferentiated hESC
lines than in neural cell derivatives. In addition, CD326-positive hESCs produced teratomas in SCID mouse testes, whereas
CD362-negative neural populations did not. Thus, CD326 may be useful as a novel marker of undifferentiated hESCs
to exclude undifferentiated hESCs from differentiated neural cell populations prior to transplantation.
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Human embryonic stem cells (hESCs) are pluripotent cells
derived from the inner cell mass of preimplantation embryos.
114 M. Sundberg et al.that can be expanded in large amounts in culture in an
undifferentiated state (Reubinoff et al., 2000; Thomson et al.,
1998). The expression of specific markers is linked to the
maintenance of hESC pluripotency and self-renewal. Such
markers include the transcription factors Oct-4 and Nanog
(Hart et al., 2004; Reubinoff et al., 2000) and various cell
surface markers, such as the stage-specific embryonic
glycolipid antigens (SSEA) 3 and 4, the keratan sulfate-related
antigens TRA-1-60 and TRA-1-81, and alkaline phosphatase
(Inzunza et al., 2005; Reubinoff et al., 2000; Thomson et al.,
1998). SSEA-3 and SSEA-4, however, are not critical for
maintaining hESC pluripotency (Brimble et al., 2006). The
results of a recent large study by the International Stem Cell
Initiative (ISCI) indicated that a significant proportion of hESC
lines do not express SSEA-3 (ISCI, 2007). Also, SSEA-4 is
expressed by a subset of dorsal root ganglion cells (Holford et
al., 1994), by dissociated fetal forebrain and spinal cord
tissues (Piao et al., 2006), and by early neuroepithelial cells in
the developing forebrain (Barraud et al., 2007).
Human ESCs can differentiate into all cell types of the
human body. By following established differentiation proto-
cols, hESCs may be induced to differentiate into cells ofFigure 1 Immunofluorescent staining to characterize undifferentia
O, S) Oct-4 and (D, H, L, P, T)merged TRA-1-81 andOct-4 images. (A, E
H) HS346, (I–L) HS360, (M–P) HS362, (Q–T) HS401. Scale bar, 200 μmneuroectodermal lineage, producing cells of neural origin
(Carpenter et al., 2001; Reubinoff et al., 2001; Zhang et al.,
2001). Early neural differentiation is characterized by the
expression of the neuroectodermal transcription factors
Pax6 and Sox1, the intermediate filament protein nestin,
and the neural cell adhesion molecule (NCAM, CD56) (Nat et
al., 2007; Reubinoff et al., 2001; Zhang et al., 2001).
Maturing neurons are distinguished by morphologic features
and express the neural markers β-tubulinIII, microtubule-
associated protein-2 (MAP-2), and neurofilament proteins,
among others (Nat et al., 2007; Reubinoff et al., 2001; Zhang
et al., 2001). Upon transplantation, hESC-derived neural
progenitor cells positive for the markers Pax6, nestin, and
NCAM integrate into the host brains of newborn mice,
migrate, and differentiate into neurons, astrocytes, and
oligodendrocytes (Reubinoff et al., 2001; Zhang et al., 2001).
Thus, neural cells derived from hESCs are a possible donor
source for cell transplants to be used in the treatment of
various neurodegenerative injuries and diseases (Reubinoff
et al., 2001; Zhang et al., 2001). Due to the risk of teratoma
formation, however, the transplanted neural population
should not contain any undifferentiated hESCs.ted hESCs. hESCs expressing (B, F, J, N, R) TRA-1-81 and (C, G, K,
, I, M, Q) Nuclear staining is shown in blue (DAPI). (A–D) HS181, (E–
.
115A novel CD marker for exclusion of pluripotent stem cellsCluster of differentiation (CD) markers are surface
proteins that belong to several different classes, such as
integrins, adhesion molecules, glycoproteins, and receptors.
Antibodies recognizing CD markers are frequently used to
identify and characterize various cell populations. The CD
markers associated with pluripotent hESCs are CD9, CD24,
and CD133 (Assou et al., 2007; Bhattacharya et al., 2004;
Carpenter et al., 2004; Lian et al., 2006; Skottman et al.,
2005; Zambidis et al., 2005). In addition, hESCs express
markers such as CD29, CD90, and CD117 (Carpenter et al.,
2004; Draper et al., 2002; Lian et al., 2006; Xu et al., 2001).
These and other markers are also associated with neural
stem cells (NSCs) and neural precursor cells (NPCs) and with
mature neurons and/or glial cells in the adult human centralFigure 2 Flow-cytometric analysis of undifferentiated hESCs. Repr
and CDmarker expression by undifferentiated TRA-1-81-positive hESC
CD90, (I) CD117, (J) CD133, (K) CD166, and (L) CD326.nervous system (CNS) and peripheral nervous system
(Supplemental Table 1).
Thus, CD markers are a useful tool for studying the
differentiation of living cells (Pruszack et al., 2007).
Furthermore, these markers can be used to isolate specific
cell populations based on their surface marker expression
profile using techniques such as immunopanning, magnetic
cell sorting, and fluorescence-activated cell sorting (FACS).
For example, CD133+ human CNS stem cells isolated from
fetal brain tissue using FACS differentiate into neural cells
when engrafted into the brains of immunodeficient new-
born mice (Tamaki et al., 2002; Uchida et al., 2000). The
hESC-derived neural populations must be carefully char-
acterized and purified prior to transplantation to avoidesentative FACS plots of hESC line HS181 expressing (A) TRA-1-81,
s: (B) CD9, (C) CD10, (D) CD24, (E) CD29, (F) CD49f, (G) CD56, (H)
116 M. Sundberg et al.tumor formation in vivo caused by undifferentiated hESCs.
To characterize the cells, the expression patterns of
specific markers in undifferentiated hESCs need to be
validated.
In this study, the expression of a panel of CD markers,
some of which were previously associated with hESCs, was
compared in five hESC lines derived and cultured similarly
(Hovatta et al., 2003, Inzunza et al., 2005). An expanded
panel consisting of 30 surface markers was used to
characterize undifferentiated TRA-1-81-positive hESCs and
their neural derivatives. The expression patterns of the most
interesting CDmarkers were further studied in two hESC lines
derived and cultured in-house.Results
hESC culture and neural differentiation
The undifferentiated state of hESCs was confirmed by positive
staining for Nanog, Oct-4, and TRA-1-81 (Figs. 1 and 4), and
SSEA-3 (data not shown), and by expression of Nanog and Oct-
4 (Supplemental Fig. 1). The neural cultures were monitored
and characterized morphologically using the Cell-IQ online
monitoring culture platform (Supplemental Movie 1) and
immunocytochemically using MAP-2 (Supplemental Fig. 2),
nestin, β-tubulinIII, BLBP, and GFAP (data not shown here, see
Nat et al., 2007). The expression of Pax6, nestin, Mash1, and
MAP-2was confirmed in neural cultures (Supplemental Fig. 1).
Surface protein expression profiles of hESCs
The hESCs (from lines HS181, HS346, HS360, HS362, and
HS401) were labeled with TRA-1-81 to identify undifferen-
tiated cells and colabeled with 11 CD markers (CD9, CD10,
CD24, CD29, CD49f, CD56, CD90, CD117, CD133, CD166, and
CD326). Representative FACS plots are presented in Fig. 2.
The CD marker expression in undifferentiated hESCs from
five hESC lines is shown in Fig. 3. The expression profile was
categorized as follows: 0–2%, negative; 3–20%, weak;
21–50%, medium; 51–80%, medium high; N80%, high (Fig.
3). For analysis details see Supplemental Table 2.Figure 3 CD marker expression in five hESC lines. Expression of CD
HS360, HS362, and HS401, as determined by flow cytometry.Flow-cytometric analysis of undifferentiated hESCs (HS
lines) showed high expression of CD24, CD90, and CD326 in
all hESC lines (Fig. 3). As CD326 has not been previously
associated with hESCs, its expression was confirmed
immunocytochemically (Fig. 4). Staining showed that
CD326 was expressed on the surface of Oct-4 and Nanog-
positive hESCs (Fig. 4). Also, the hESC lines derived in REGEA
expressed CD326 (Figs. 4 and 5). As Fig. 3 shows, expression
of CD49f and CD133 was also high or medium high in all five
hESC lines. Expression of CD10 was medium or medium high
in all hESC lines, while that of CD9, CD56, CD117, and CD166
was weak or absent. Expression of marker CD29 was
heterogeneous in the five hESC lines analyzed, varying
from 13 to 72%.
Surface protein expression profiles of hESCs and
their neural derivatives
The HS181 line was chosen for a broader surface marker
study in which we compared the expression of 30 CD
markers on TRA-1-81-positive hESCs and their neural
derivatives. The surface protein expression profiles are
shown in Fig. 5. Similar to HS181 hESCs, neural cells
expressed high or medium high levels of CD24, CD29,
CD49f, CD59, and CD90. Expression of CD10, CD133, and
CD326 was substantially higher (N20%) in HS181 hESCs
compared to the neural derivatives. The most prominent
difference was in the expression of CD326, which was high
in undifferentiated hESCs (N90%) and weak in neural cells
(b20%). Compared to the hESCs, hESC-derived neural cells
had higher expression of CD49b, CD56, CD117, CD166,
CD184, and CD271. Of these markers, CD49b, CD146, and
CD166 have not been previously associated with
human NSCs or NPCs (for comparisons, see Fig. 5A and
Supplemental Table 1). Supplemental Fig. 3 shows repre-
sentative FACS plots of CD marker expression levels that
were substantially increased in hESC-derived neural cells.
Differentially expressed CD markers between hESCs and
neural cells were further profiled in four other hESC lines:
HS360, HS362, Regea040/06, and Regea023/08. This
analysis showed that CD133 and CD326 were expressed at
substantially higher levels in undifferentiated hESCsmarkers in TRA-1-81-positive hESCs in hESC lines HS181, HS346,
Figure 4 Immunofluorescent staining of hESC colonies expressing CD326, Oct-4, and Nanog. hESC lines: (A–H) HS362, (I–P)
Regea040/06, and (Q–X) Regea023/08. hESCs expressed (B, F, J, N, R, V) CD326, (C, K, S) Oct-4, and (G, O, W) Nanog. (D, H, L, P, T, X)
Merged CD326/Oct-4 and CD326/Nanog images. Each image also includes higher magnifications obtained with a 40× objective. (A, E, I,
M, Q, U) Nuclear staining with DAPI. Scale bar, 100 μm.
117A novel CD marker for exclusion of pluripotent stem cellscompared to their neural derivatives, while CD56 and
CD184 expression was higher in neural cells (Fig. 5).Neural subpopulations and FACS sorting
Double labeling showed that CD56- (NCAM) and MAP-2-
positive neural populations were not positive for CD326, a
finding confirmed by combinatorial FACS analysis (Fig. 6).
Subpopulations of CD56- and MAP-2-positive neural cells
were positive for CD184 that especially localized to neurites
in MAP-2-positive neurons (Fig. 6). Combinatorial FACS
analysis showed that 48.8% of neural cells were CD56+/
CD184+ (Fig. 6).Neural cell sorting was performed using either positive
selection for CD56, CD117, CD133, CD166, CD184, and CD271
or negative selection for CD326. The viability and neuronal
morphology of sorted cells was monitored for 3 days after
subcultivation (Supplemental Movie 2) and the results
showed that cells in the original neural populations and in
CD326−, CD56+, and CD184+ populations resembled typical
neurons (Fig. 6). FACS-sorted cells were 34 to 64% positive for
MAP-2 (Supplemental Fig. 2). Especially, CD56+ and CD184+
cell populations were highly (N60%) positive for MAP-2. No
GFAP-positive cells were identified.
Additional teratoma formation experiments with
SCID mice revealed that undifferentiated hESCs formed
teratomas, whereas neural cells and CD326-negative neural
Figure 5 CD marker expression in hESCs and their neural derivates. (A) Expression of 30 different CD markers in TRA-1-81-positive
hESCs (HS181) and neural derivatives determined by flow cytometry. (B) The expression of CD49b, CD56, CD117, CD133, CD166, CD184,
CD271, and CD326 in TRA-1-81-positive hESCs and hESC-derived neural cells, determined by flow cytometry.
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(Supplemental Fig. 4).
Downregulation of pluripotent markers and
upregulation of neural markers during
differentiation
Next, we studied the more detailed expression profiles of
specific markers during the differentiation of hESCs toward
neural cells. The expression of Oct-4 and Nanog was
gradually downregulated during the first 4 weeks of
differentiation at which time the endo- and mesodermal
markers also vanished. Expression of Pax-6 and nestin was
constant, while expression of Mash1, MAP2, and CXCR4
appeared after 1 week of differentiation and remained quite
constant thereafter (Supplemental Fig. 1).
The surface expression of the pluripotency marker TRA-1-
81 was downregulated in parallel with CD326 during 3 weeks
of neural differentiation. The expression of CD133 varied but
was downregulated in 6 weeks' time. CD56 was highlyupregulated already during the first week of differentiation
and remained high during the 6-week time course. CD184
expression followed the expression curve of CD56 at a lower
level (Fig. 7).
The combinatorial FACS analysis revealed that 88% of
CD133+ cells were positive for CD326 in hESCs (day 0). After 3
weeks, less than 8% of CD133+ cells were CD326 positive.
Interestingly, the CD184+ subpopulation in CD56+ cells
increased from 28 up to 46% during 6 weeks of differentia-
tion, further confirming that CD184 is expressed in differ-
entiating neural cell populations (Fig. 7).
Discussion
In this study, the expression of 30 CD surface markers on TRA-
1-81-positive hESCs and their neural derivatives was char-
acterized. The CD expression profiles of seven hESC lines
were analyzed and compared between undifferentiated
hESCs and their neural derivatives. Here, we showed that
similarly derived and cultured hESC lines had relatively
Figure 6 Immunofluorescent staining of neural populations showed that cells positive for (A) CD56 (NCAM, green) and (B) MAP-2
(green) were not positive for CD326 (red). (C, D) CD56- and MAP-2-positive cells coexpressed CD184 (red). Combinatorial FACS analysis
showed that (F) the majority of neural cells were CD56+ (∼77%) and only a minor population was CD56+/CD326+ (∼9%), (H) whereas
∼49% of cells were CD56+/CD184+. (E, G) Unlabeled neural cells were used for population determination. The morphology of (I)
unsorted neural cells and (J) CD326−-, (K) CD56+-, and (L) CD184+-sorted populations is presented. Scale bar, 100 μm.
119A novel CD marker for exclusion of pluripotent stem cellsconstant CD marker expression levels, whereas neural
populations derived from different hESC lines had more
variable CD marker expression levels. The expression of
CD133 and CD326 was strong in undifferentiated hESCs and
low in neural derivatives, and the expression of CD56 and
CD184 was increased in hESC-derived neural cells. These CD
marker expression results were similar in hESCs derived in
two laboratories.
A detailed characterization of undifferentiated hESCs and
their derivatives is important for many reasons. First, it is
important to determine the similarity of hESCs derived and
cultured by different laboratories, as recently investigated
by the ISCI (ISCI, 2007). For example, their analysis of 59
hESC lines revealed large variability between different hESC
lines in the expression of the surface markers SSEA-3 and
SSEA-4 (ISCI, 2007). Here, we used TRA-1-81, which is more
consistently expressed by undifferentiated hESCs (ISCI,
2007), as a comarker in CDmarker screening for the selection
of undifferentiated hESCs. Second, novel surface markers
that are highly and consistently expressed in all undiffer-
entiated hESC lines would enable separation of undiffer-
entiated hESCs from their neural derivatives. In
heterogeneous populations, this would enable the exclusion
of pluripotent cells that can form teratomas in vivo. This
negative selection may be needed to produce safe neural cell
grafts for transplantation therapies. Further, negative-
selected populations do not contain surface-bound anti-bodies, in contrast to positive-selected populations, a
difference that may have a large impact on graft survival.
Here, we showed that all five of the undifferentiated
hESC lines analyzed had a consistently high expression of
CD24, CD90, and CD133, markers that were previously
associated with hESCs. In this study, more than 80% of
hESCs expressed CD24 and CD90, whose gene and protein
products have been identified in hESCs (Draper et al., 2002;
Skottman et al., 2005). CD24 can be used to distinguish hESCs
from fibroblasts in culture (Assou et al., 2007) and to
distinguish mouse multipotent fetal stem cells from neural
progenitors and postmitotic neurons (Panchision et al.,
2007). Pruszack and co-workers suggested that CD24 is a
specific surface marker that is upregulated during neural
differentiation (Pruszack et al., 2007). In contrast, our study
shows that hESCs and hESC-derived neural cells expressed
CD24 at equal levels (90% vs 94%, respectively). Also, high
(N90%) expression of CD90 was detected in both undiffer-
entiated hESCs and hESC-derived neural cells, which is
consistent with the results of previous studies (Schwartz
et al., 2003; Draper et al., 2002; Hamann et al., 1980).
Hence, our data exclude the potential use of CD24 and CD90
as specific markers for undifferentiated hESCs or differen-
tiating hESC-derived neural cells. In contrast, CD133 marker
expression was over 65% in all undifferentiated hESC lines
and was downregulated in hESC-derived neural cells. This
finding is consistent with the literature and suggests that
Figure 7 Time-point analysis of hESC (HS360) neural differ-
entiation. (A) Expression curves of TRA-1-81+, CD326+, CD133+,
CD56+, and CD184+ populations from 0 to 46 days of neural
differentiation. (B) CD326 expression in the CD133+ subpopula-
tion and (C) CD184 expression in the CD56+ subpopulation.
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(Carpenter et al., 2004; Schwartz et al., 2003; Yin et al.,
1997). CD133 can also be used as a selection marker for
proliferating neural stem and precursor populations from
postmitotic neurons (Uchida et al., 2000). Moreover, we
suggest that the downregulation of CD133 expression in
differentiating neural cells indicates their decreasing pro-
liferation capacity compared to undifferentiated hESCs.
Most interestingly, we found a novel surface marker,
CD326, consistently expressed in over 94% of the undiffer-
entiated cells in all seven hESC lines studied. This result was
constant between hESC lines derived in two independent
laboratories. CD326, also known as epithelial cell adhesionmolecule (EpCAM), is a glycoprotein involved in cell adhesion
(Litvinov et al., 1997). The high expression of CD326 by
hESCs might explain the tight cell-to-cell contacts of hESCs in
colonies. CD326 is associated with stem cells in hepatic cell
lineages (Schmelzer et al., 2006). CD326/EpCAM is
also part of the same epithelial adhesion molecule family as
E-cadherin, which is expressed in undifferentiated hESC
colonies but not in differentiated embryoid bodies (Cai et
al., 2005; Ullmann et al., 2007). In carcinoma cells, CD326/
EpCAM affects upregulation of the proto-oncogene c-myc and
cyclin A/E and thereby has direct impact on the cell cycle and
proliferation (Munz et al., 2004). Thus, this molecule might
also affect the ability of hESCs to proliferate efficiently.
Importantly, both flow-cytometric and immunocytochemical
analyses showed that hESC-derived neural populations did not
contain CD362-positive cells. Moreover, expression of CD362
was downregulated in parallel with TRA-1-81 on hESC-derived
populations during the first 4 weeks of neural differentiation.
Further, combinatorial FACS analysis showed that the CD133+/
CD326+ population was downregulated during differentiation.
Thus, we propose that CD326 can be used as a novel marker
for undifferentiated hESCs to facilitate the removal of
undifferentiated hESCs from differentiated neural cell
populations before cell transplantation.
Some markers previously associated with hESCs, such as
CD9, CD29, and CD117 (Assou et al., 2007; Bhattacharya et
al., 2004; Carpenter et al., 2004; Draper et al., 2002; Lian et
al., 2006; Xu et al., 2001; Zambidis et al., 2005) were only
weakly or heterogeneously expressed by our undifferen-
tiated hESCs. CD marker expression during neural differ-
entiation of hESCs appears to vary depending on both the
differentiation protocol used and the initial expression
profile in hESCs. Previously, Pruszack and co-workers
performed flow-cytometric analysis and sorting on hESCs
and neural cells differentiated in a coculture system (Pruszak
et al., 2007). The expression levels of stem-cell-related
markers CD24, CD29, and CD133 were less than 15% in the
hESC lines HI and H7 (Pruszak et al., 2007), compared to
much higher expression in our undifferentiated hESCs. These
differences may reflect the different derivation and cultur-
ing methods of hESCs and further imply that universal,
constantly highly expressed markers for hESCs are needed.
There are currently many differentiation protocols for
neural differentiation of hESCs utilizing adherent, suspen-
sion, and cocultures with various supplements (Hoffman and
Carpenter, 2005). Thus, the neural cell cultures are often
heterogeneous, impure, and not necessarily comparable
with one another. Here, we used simple methods for neural
differentiation and compared the CD profiles in these
cultures to the undifferentiated hESCs. In our study, the
neural cells derived from five hESC lines had increased
expression of CD56 and CD184 compared to undifferentiated
hESCs, whereas the expression of CD49b, CD177, CD166, and
CD271 was heterogeneously increased. CD56 is a marker of
early neuroectodermal differentiation (Reubinoff et al.,
2001) and has been used to identify neural differentiation
of hESCs by flow-cytometric analysis and sorting (Pruszak et
al., 2007). CD184, also known as the chemokine receptor
CXCR4, is characterized as a receptor protein modulating
cell growth and migration of neural cells in the CNS (Ni et al.,
2004). Interestingly, in our study the hESC-derived neural
cells had quite similar expression levels of CD184 compared
121A novel CD marker for exclusion of pluripotent stem cellsto NPCs derived from human fetal brain tissues (Ni et al.,
2004), suggesting that these cell populations might have
similar migration capacities.
The more detailed analysis of the differentiating neural
populations revealed that both gene and surface protein
markers for pluripotent cells disappeared during the first 4
weeks of differentiation. These time curves for TRA-1-81 and
CD326 expression were very similar to those described for
TRA-1-81, TRA-1-60, SSEA-3, and SSEA-4 in a coculture
system (Pruszak et al., 2007). In addition, the expression of
CD56 was rapidly upregulated in differentiating neural
populations and remained high during 6 weeks of differentia-
tion. These results are in line with a previous study (Pruszak
et al., 2007), suggesting that CD56 can be used to monitor
neural specification. Moreover, our neural cell population did
not produce teratomas when transplanted into SCID mice.
This implies that our hESC-derived neural cell cultures are
valid populations for further production of more specialized
neural cells or for transplantation.
As expression of CD184 was increased in parallel with CD56,
we performed combinatorial FACS analysis with CD56 and
CD184. These results showed that during 5 to 6 weeks of
differentiation up to 50% of CD56-positive cells were CD184
positive. Further, CD184 localized in soma and neurites of
CD56+ cells and especially in MAP-2-positive neurons. FACS-
sorted CD184+ neural cells, followed with time-lapse imaging,
matured into viable neurons. These results are in line with a
previous study by Peng and co-workers (Peng et al., 2007),who
showed that human fetal brain tissue-derived NPCs also
express CD184 at high levels when differentiated into neuronal
cells. Altogether, these results suggest that CD184 is an
important factor in neurogenesis and inmaturation of neuronal
cells and should be studied in more detail in the future.
Fluorescence-activated cell sorting has been considered
as a possible method for producing pure neural subpopula-
tions to be used in transplantation therapies (Chung et al.,
2006; Guzman et al., 2008). Here, we showed that neural
subcultivation is possible after sorting with various CD
markers, CD56, CD117, CD133, CD166, CD184, and CD271.
Especially, by sorting with CD56 and CD184 viable neuronal
populations can be produced. Moreover, pluripotent cells can
be eliminated by negative sorting for CD326 if more
purification of the neural population is needed prior to
transplantation. Although there are milder and more
sensitive ways to sort with FACS using a bigger nozzle
(100 µm) and low sorting setups for fragile cells, this method
needs to be better optimized before separating populations
for cell grafting. For these types of studies, microfluidics-
based cell sorting techniques may be a future prospect
(Studer et al., 2004; Chen et al., 2008). In any case, FACS is a
usable and reliable method for studies of neural subpopula-
tions and their characteristics.
In conclusion, surface marker expression in previously
established hESC lines varies to a great extent universally,
whereas hESC lines derived and cultured similarly have quite
constant CD marker profiles. Even though there are many
commonly used markers for hESCs (SSEA-3, SSEA-4, TRA-1-
60, TRA-1-81), their expression levels vary markedly in
different hESC lines. In contrast, CD326 showed consistently
high expression in all undifferentiated hESCs compared to
their neural derivatives. CD326 has not, to our knowledge,
been previously associated with hESCs, and therefore weconsider this surface protein to be a novel marker for
undifferentiated hESCs. As our transplantation experiments
showed no teratoma formation with hESC-derived CD326-
negative selected neural cells, we conclude that this marker




Five hESC lines were used in this study: HS181, HS346, HS360,
HS362, and HS401. All hESC lines were derived from the inner
cell mass of supernumerary blastocyst-stage embryos at the
Karolinska Institute, Karolinska University Hospital Hud-
dinge, Sweden, after approval by the ethics committee of
the Karolinska Institute. The procedures for the derivation,
characterization, and culture of these hESC lines were
described previously (Hovatta et al., 2003). Studies utilizing
the hESC lines derived at the Karolinska Institute and
performed at REGEA, Institute for Regenerative Medicine,
University of Tampere, Finland, were approved by the ethics
committee of the Hospital District of Pirkanmaa (Hovatta,
R05051). In REGEA, two novel hESC lines, Regea040/06 and
Regea023/08, were derived and cultured (H. Skottman et
al., unpublished data). REGEA has a supportive statement
from the ethics committee of the Pirkanmaa Hospital district
to derive and expand new human ESC lines from surplus
embryos, which cannot be used in the infertility treatment of
the donating couples (Skottman, R05116). All the hESCs were
cultured on commercially available, mitotically inactivated
human foreskin fibroblasts (CRL-2429, ATCC, Manassas, VA,
USA) in hESC medium consisting of knockout Dulbecco's
modified Eagle's medium (Gibco Invitrogen, Carlsbad, CA,
USA) supplemented with 20% knockout SR (Gibco Invitrogen),
2 mM GlutaMax (Gibco Invitrogen), 0.1 mM minimal essential
medium nonessential amino acids (Cambrex Bio Science,
Karlskoga, Sweden), 0.1 mM β-mercaptoethanol (Gibco
Invitrogen), 50 U/ml penicillin/streptomycin (Cambrex),
and 8 ng/ml basic fibroblast growth factor (bFGF; R&D
Systems, Minneapolis, MN, USA) at 37 °C in 5% CO2 in a
humidified atmosphere. The hESC colonies were passaged at
5- to 7-day intervals by mechanical splitting and replated on
fresh feeder cells.
Neural differentiation of hESCs
HS181, HS360, HS362, Regea040/06, and Regea023/08
colonies were mechanically dissected and differentiated
into neural cells in adherent or suspension culture using a
modified protocol by Nat and co-workers (Nat et al., 2007).
The neural proliferation medium contained Dulbecco's
modified Eagle's medium/F-12 and neurobasal medium
(1:1) supplemented with 1× B27, 1× N2, 2 mM GlutaMax (all
from Gibco Invitrogen), 25 U/ml penicillin/streptomycin,
and 20 ng/ml bFGF. Briefly, differentiating neural cells
formed rosette-like structures in adherent culture (CellBIND
Surface, Corning, Inc., Corning, NY, USA) or in suspension
culture in proliferation medium after 7 to 10 days. These
rosette structures were dissected and plated on laminin-
coated (10 μg/ml; Sigma Chemical Co., St. Louis, MO, USA)
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of bFGF (neural differentiation medium) for further adherent
culturing for 6 to 8 weeks. In suspension culture, the spheres
were mechanically split once a week and cultured for 6 to 8
weeks. Thereafter, spheres were dissected and replated on
laminin-coated well plates for 1 week. bFGF (4 ng/ml) and
brain-derived neurotrophic factor (5 ng/ml; Gibco Invitro-
gen) were added to cultures to support the growth and
survival of maturing neural cells. All cultures were main-
tained in a humidified atmosphere at 37 °C and 5% CO2.
Automated monitoring of hESC-derived neural cells
The growth and morphologic characteristics of hESC-derived
neural cells were monitored prior to immunocytochemical
and flow-cytometric analysis using an online cell culture
platform (Cell-IQ, Chip-Man Technologies, Tampere, Finland)
equipped with phase-contrast microscope optics (10×) and a
CCD camera, as described previously for hESCs (Narkilahti et
al., 2007). This software allows time-lapse imaging of
500 × 670-μm areas in the culture wells. Captured images
(JPEG) were saved in separate folders and converted into
movie format using Cell-IQ analysis software.
Immunocytochemical analysis of hESCs and
hESC-derived neural cells
Subsets of hESCs and hESC-derived neural cells were fixed
using 4% paraformaldehyde in phosphate-buffered saline
(PBS; 0.01 M PBS, pH 7.4) for 20 min at room temperature
and washed twice with PBS. The cells were permeabilized
and blocked with 10% normal donkey serum (NDS; Sigma) and
1% bovine serum albumin (BSA; Sigma) in PBS containing 0.1%
Triton X-100 for 45 min at room temperature. Primary
antibodies were applied overnight at 4 °C in 1% BSA, 1% NDS
in PBS containing 0.1% Triton X-100. Cells were washed three
times and incubated with fluorescent secondary antibodies
in 1% BSA in PBS for 60 min at room temperature in the dark.
Cells were then washed two times with PBS and two times
with phosphate buffer and mounted using Vectashield
containing 4′,6-diamidino-2-phenylindole (DAPI) for nuclear
staining (Vector Laboratories, Inc., Burlingame, CA, USA).
The primary antibodies used for hESCs were mouse anti-
epithelial-specific antigen IgG (EpCAM/CD326, 1:200; Che-
micon, Temecula, CA, USA), goat anti-Nanog IgG (1:200; R&D
Systems), goat anti-Oct-4 IgG (1:100; R&D Systems), and
mouse anti-TRA-1-81 IgM (1:200; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA). Primary antibodies used for
neural cells were mouse anti-CXCR4 IgG (1:2000; R&D
Systems), sheep anti-GFAP IgG (1:600; R&D Systems), rabbit
anti-MAP-2 IgG (1:600–1:800; Chemicon), and rabbit anti-
NCAM IgG (1:800; Chemicon). Secondary antibodies used
were Alexa Fluor 488 donkey anti-goat IgG (1:800), Alexa
Fluor 488 donkey anti-rabbit IgG (1:400), Alexa Fluor 488
donkey anti-sheep IgG, and Alexa Fluor 568 goat anti-rabbit
IgG (1:400) (all from Molecular Probes Invitrogen) and
rhodamine red-conjugated donkey anti-mouse IgM and IgG
(1:400; Jackson ImmunoResearch Europe Ltd., Cambridge-
shire, UK). For negative controls, the primary antibodies
were omitted from the immunostaining, which resulted in
the disappearance of all staining. Stained cells were viewedand photographed using an Olympus IX51 phase-contrast
microscope equipped with fluorescence optics and an
Olympus DP71 camera.
Sample preparation for flow cytometry
The hESC cultures were washed once with ice-cold sterile PBS
and trypsinized for 10 min at 37 °C (trypsin–EDTA; BioWhit-
taker, Fisher Scientific, Leicestershire, UK) and inactivated
with 2% fetal bovine serum (FBS; Gibco Invitrogen) in PBS.
Cell colonies were dissociated into single-cell suspensions by
trituration, centrifuged, resuspended in 2% FBS in PBS, and
counted using trypan blue exclusion to identify viable cells.
Aliquots of 100,000 viable cells per sample were used for
flow-cytometric analysis. hESC-derived neural cells were
washed twice, trypsinized for 5 min at 37 °C, and inactivated
with 5% human serum (HS) in PBS. Cells were dissociated into
a single-cell suspension by trituration, centrifuged, resus-
pended in 5% HS in PBS, and filtered using 50-μmcell strainers
(CupFilcons; BD Biosciences, Franklin Lakes, NJ, USA) prior to
trypan blue counting. Aliquots of 100,000 viable cells per
sample were used for flow-cytometric analysis.
Surface antigen expression analysis
To identify undifferentiated cells, hESCs were labeled for
TRA-1-81 and colabeled with fluorochrome-conjugated anti-
human CD markers. Briefly, hESCs were incubated for 15 min
at 4 °C with TRA-1-81 antibody, followed by incubation with
fluorescent secondary antibody and antibodies recognizing
CD markers for 15 min at 4 °C in the dark. Cells were washed
twice with 2% FBS in PBS between each step. Thereafter,
labeled cells were suspended in 2% FBS in PBS. At least three
parallel samples for each TRA-1-81 and CD marker combina-
tion were analyzed. hESC-derived neural cells were directly
labeled with anti-human CD markers and suspended in 5% HS
in PBS. Two to four parallel samples for each CD marker were
analyzed.
The primary antibody used was mouse anti-TRA-1-81 IgM
(1:200; Santa Cruz Biotechnology) with secondary antibody
anti-mouse Alexa Fluor 488 IgM (1:6500; Molecular Probes
Invitrogen) or anti-mouse phycoerythrin (PE) IgM (1:500;
Caltag Invitrogen). Antibodies recognizing CD markers were
CD4–fluorescein isothiocyanate (FITC), CD9–FITC, CD13–PE,
CD24–FITC, CD31–FITC, CD34–allophycocyanin (APC), CD38–
PE, CD44–FITC, CD49b–FITC, CD56–PE, CD59–FITC, CD61–
FITC, CD71–PE, CD99R–FITC (ImmunoTools, Friesoythe,
Germany); CD45–FITC, CD117–APC, CD133–PE, CD271–
FITC, CD326–APC (Miltenyi Biotech, Bergisch Gladbach,
Germany); CD9–PE, CD10–PE–Cy7, CD29–APC, CD49d–PE,
CD49f–APC, CD90–APC, CD106–PE–Cy5, CD146–PE, CD166–
PE, CD184–PE–Cy5 (BD Biosciences); and CD105–PE and
CD144–PE (R&D Systems). Antibody concentrations were
chosen according to the manufacturer's protocol or adjusted
to the optimal concentration when necessary. Background
fluorescence was excluded using unlabeled cells or isotype
controls or by incubation with secondary antibodies only.
Analyses were performed using FACSAria equipment with 488-
and 633-nm lasers, a standard filter set, and FACSDiva
software (BD Biosciences). The cell population of interest
was determined and dead cells were excluded using forward-
123A novel CD marker for exclusion of pluripotent stem cellsand side-scatter parameters. For each sample run, 10,000 to
20,000 events were recorded and analyzed.
Fluorescence-activated cell sorting and
subcultivation of hESC-derived neural cells
HS181-derived neural cell samples (400,000–1,000,000 cells/
sample) were prepared as described above and labeled for
CD56, CD117, CD133, CD166, CD184, or CD271. Cell sorting
was performed using a FACSAria with a 100-μm nozzle,
20.00 psi sheath pressure, sort precision mode set for purity,
flow rate 2, and plates voltage 5.0 (sort setup: low). Live cells
were gated using forward- and side-scatter parameters, and
cells positive for each CD marker were collected into 5-ml
polystyrene tubes (BD Biosciences) in neural differentiation
medium. Cells were centrifuged and resuspended in medium
containing 4 ng/ml bFGF and 5 ng/ml brain-derived neuro-
trophic factor and plated onto laminin-coated culture plates.
After 3 days, the FACS-sorted cells were monitored with Cell-
IQ for 24 h, fixed, and stained using antibodies for MAP-2 and
GFAP, as described above.
Teratoma formation
To study teratoma formation, hESCs and hESC-derived neural
cell populations were transplanted into SCID mouse testes as
previously described (Hovatta et al., 2003; Inzunza et al.,
2005). After the cell injections of hESCs, 200,000 cells/testis
(n=3); neural cells, 1,000,000 cells/testis (n=7); and CD326-
negative neural cells, 1,000,000 cells/testis (n=3), the
animals were followed for 2 months for teratoma formation.
Time-point analysis of specific markers during
neural differentiation
The more detailed time-point analyses of specific markers
were performed with HS360 during the neural differentia-
tion. The cells were first grown in suspension for 0, 7, 14, 19,
28, 35, or 42 days. Thereafter, they were in vitro
differentiated on laminin-coated wells for 4 days as
described above. Thus, the samples for gene expression
(RT-PCR) and FACS analysis were collected at days 0, 11, 18,
23, 32, 39, and 46.
For RT-PCR, the expression of the pluripotent markers
Nanog and Oct4; the endodermal marker α-fetoprotein; the
mesodermal marker brachyury; the neural markers MAP-2,
Mash1, nestin, and Pax6; C-X-C chemokine receptor type 4;
and the housekeeping gene GAPDH was analyzed. For RT-
PCR, RNA was extracted using the RNeasy Micro Kit (Qiagen,
Hilden, Germany). A total of 50 ng of RNA was used for cDNA
synthesis (Sensiscript RT Kit; Qiagen) according to the
manufacturer's instructions. Each PCR contained 700 ng of
cDNA, 0.25 μM forward and reverse primers, 1× Taq buffer
(−MgCl, +KCl) (Fermentas, Leon-Rot, Germany), 2.5 mM
dNTP (Fermentas), 25 mM MgCl (Fermentas), dH2O, and 0.6 U
Taq DNA polymerase enzyme (Fermentas). PCR program
parameters were denaturation at 95 °C for 3 min followed
with 35 cycles of 95 °C for 30 s, 55 °C for 30 s, and 72 °C for
1 min and a final extension for 5 min in 72 °C.
For FACS analysis, the expression of TRA-1-81, CD326,
CD133, CD56, and CD184 was analyzed. In addition, combi-natorial analyses for CD133/CD326, CD56/CD326, and CD56/
184 were performed. All FACS analyses were performed as
described above.
Acknowledgments
We thank the personnel of REGEA, Institute for Regenera-
tive Medicine, for their support and assistance in stem cell
research. This study was supported by Academy of Finland,
The Finnish Funding Agency for Technology and Innovation
TEKES, The Competitive Research Fund of the Pirkanmaa
Hospital District, The Employment and Economic Develop-
ment Center for Pirkanmaa, The Finnish Defense Forces,
the Jenny and Antti Wihuri Foundation, and the Swedish
Research Council.
Appendix A. Supplementary data
Supplementary data associatedwith this article can be found,
in the online version, at doi:10.1016/j.scr.2008.08.001.
References
Assou, S., Lecarrour, T., Tondeur, S., Strom, S., Gabelle, A., Marty,
S., Nadal, L., Pantesco, V., Reme, T., Hugnot, J.P., Gasca, S.,
Hovatta, O., Hamamah, S., Klein, B., De Vos, J., 2007. A meta-
analysis of human embryonic stem cells transcriptome inte-
grated into a web-based expression atlas. Stem Cells 25,
961–973.
Barraud, P., Stott, S., Mollgard, K., Parmar, M., Bjorklund, A., 2007.
In vitro characterization of a human neural progenitor cell
coexpressing SSEA4 and CD133. J. Neurosci. Res. 85, 250–259.
Bhattacharya, B., Miura, T., Brandenberger, R., Mejido, J., Luo, Y.,
Yang, A.X., Joshi, B.H., Ginis, I., Thies, R.S., Amit, M., Lyons, I.,
Condie, B.G., Itskovitz-Eldor, J., Rao, M.S., Puri, R.K., 2004.
Gene expression in human embryonic stem cell lines: unique
molecular signature. Blood 103, 2956–2964.
Brimble, S.N., Sherrer, E.S., Uhl, E.W., Wang, E., Kelly, S., Merrill Jr.,
A.H., Robins, A.J., Schulz, T.C., 2006. The cell surface glyco-
sphingolipids SSEA-3 and SSEA-4 are not essential for human ESC
pluripotency. Stem Cells 25, 54–62.
Cai, J., Olson, J.M., Rao, M.S., Stanley, M., Taylor, E., Ni, H.T., 2005.
Development of antibodies to human embryonic stem cell
antigens. BMC Dev. Biol. 5, 26.
Carpenter, M.K., Inokuma, M.S., Denham, J., Mujtaba, T., Chiu, C.P.,
Rao, M.S., 2001. Enrichment of neurons and neural precursors
from human embryonic stem cells. Exp. Neurol. 172, 383–397.
Carpenter, M.K., Rosler, E.S., Fisk, G.J., Brandenberger, R., Ares, X.,
Miura, T., Lucero, M., Rao, M.S., 2004. Properties of four human
embryonic stem cell lines maintained in a feeder-free culture
system. Dev. Dyn. 229, 243–258.
Chen, P., Feng, X., Du, W., Liu, B.F., 2008. Microfluidic chips for cell
sorting. Front. Biosci. 13, 2464–2483.
Chung, S., Shin, B.S., Hedlund, E., Pruszak, J., Ferree, A., Kang, U.J.,
Isacson, O., Kim, K.S., 2006. Genetic selection of sox1GFP-
expressing neural precursors removes residual tumorigenic
pluripotent stem cells and attenuates tumor formation after
transplantation. J. Neurochem. 97, 1467–1480.
Draper, J.S., Pigott, C., Thomson, J.A., Andrews, P.W., 2002. Surface
antigens of human embryonic stem cells: changes upon differ-
entiation in culture. J. Anat. 200, 249–258.
Guzman, R., De Los Angeles, A., Cheshier, S., Choi, R., Hoang, S.,
Liauw, J., Schaar, B., Steinberg, G., 2008. Intracarotid injection
of fluorescence activated cell-sorted CD49d-positive neural stem
124 M. Sundberg et al.cells improves targeted cell delivery and behavior after stroke in
a mouse stroke model. Stroke 39, 1300–1306.
Hamann, A., Arndt, R., Klein, P., Thiele, H.G., 1980. Isolation and
characterization of the thymus-brain antigen (analogous to thy-1
antigen) from human brain. Biochem. J. 187, 403–412.
Hart, A.H., Hartley, L., Ibrahim, M., Robb, L., 2004. Identification,
cloning and expression analysis of the pluripotency promoting
Nanog genes in mouse and human. Dev. Dyn. 230, 187–198.
Hoffman, L.M., Carpenter, M.K., 2005. Characterization and culture
of human embryonic stem cells. Nat. Biotechnol. 23, 699–708.
Holford, L.C., Case, P., Lawson, S.N., 1994. Substance P, neurofila-
ment, peripherin and SSEA4 immunocytochemistry of human dorsal
root ganglion neurons obtained from post-mortem tissue: a
quantitative morphometric analysis. J. Neurocytol. 23, 577–589.
Hovatta, O., Mikkola, M., Gertow, K., Stromberg, A.M., Inzunza, J.,
Hreinsson, J., Rozell, B., Blennow, E., Andang, M., Ahrlund-Richter,
L., 2003. A culture system using human foreskin fibroblasts as
feeder cells allows production of human embryonic stem cells.
Hum. Reprod. 18, 1404–1409.
Inzunza, J., Gertow, K., Stromberg, M.A., Matilainen, E., Blennow,
E., Skottman, H., Wolbank, S., Ahrlund-Richter, L., Hovatta, O.,
2005. Derivation of human embryonic stem cell lines in serum
replacement medium using postnatal human fibroblasts as feeder
cells. Stem Cells 23, 544–549.
ISCI (International Stem Cell Initiative)Adewumi, O., Aflatoonian, B.,
Ahrlund-Richter, L., Amit, M., Andrews, P.W., Beighton, G., Bello,
P.A., Benvenisty, N., Berry, L.S., Bevan, S., Blum, B., Brooking, J.,
Chen, K.G., Choo, A.B., Churchill, G.A., Corbel, M., Damjanov, I.,
Draper, J.S., Dvorak, P., Emanuelsson, K., Fleck, R.A., Ford, A.,
Gertow, K., Gertsenstein, M., Gokhale, P.J., Hamilton, R.S.,
Hampl, A., Healy, L.E., Hovatta, O., Hyllner, J., Imreh, M.P.,
Itskovitz-Eldor, J., Jackson, J., Johnson, J.L., Jones, M., Kee, K.,
King, B.L., Knowles, B.B., Lako, M., Lebrin, F., Mallon, B.S.,
Manning, D., Mayshar, Y.,McKay, R.D., Michalska, A.E., Mikkola,M.,
Mileikovsky, M., Minger, S.L., Moore, H.D., Mummery, C.L., Nagy,
A., Nakatsuji, N., O'Brien, C.M., Oh, S.K., Olsson, C., Otonkoski, T.,
Park, K.Y., Passier, R., Patel, H., Patel, M., Pedersen, R., Pera,M.F.,
Piekarczyk,M.S., Pera, R.A., Reubinoff, B.E., Robins, A.J., Rossant,
J., Rugg-Gunn, P., Schulz, T.C., Semb,H., Sherrer, E.S., Siemen, H.,
Stacey, G.N., Stojkovic, M., Suemori, H., Szatkiewicz, J., Turetsky,
T., Tuuri, T., van den Brink, S., Vintersten, K., Vuoristo, S., Ward,
D., Weaver, T.A., Young, L.A., Zhang,W., 2007. Characterization of
human embryonic stem cell lines by the International Stem Cell
Initiative. Nat. Biotechnol. 25, 803–816.
Lian, Q., Lye, E., Yeo, K.S., Tan, E.K., Salto-Tellez, M., Liu, T.M.,
Palanisamy, N., El Oakley, R.M., Lee, E.H., Lim, B., Lim, S.K.,
2006. Derivation of clinically compliant MSCs from CD105+, CD24−
differentiated human ESCs. Stem Cells 25, 425–436.
Litvinov, S.V., Balzar, M., Winter, M.J., Bakker, H.A., Briaire-de Bruijn,
I.H., Prins, F., Fleuren, G.J., Warnaar, S.O., 1997. Epithelial cell
adhesion molecule (Ep-CAM) modulates cell–cell interactions
mediated by classic cadherins. J. Cell Biol. 139, 1337–1348.
Munz, M., Kieu, C., Mack, B., Schmitt, B., Zeidler, R., Gires, O.,
2004. The carcinoma-associated antigen EpCAM upregulates c-
myc and induces cell proliferation. Oncogene 23, 5748–5758.
Narkilahti, S., Rajala, K., Pihlajamäki, H., Suuronen, R., Hovatta,
O., Skottman, H., 2007. Monitoring and analysis of dynamic
growth of human embryonic stem cells: comparison of automated
instrumentation and conventional culturing methods. Biomed.
Eng. Online 12 (6), 11.
Nat, R., Nilbratt, M., Narkilahti, S., Winblad, B., Hovatta, O.,
Nordberg, A., 2007. Neurogenic neuroepithelial and radial glial
cell generated from six human embryonic stem cell lines in serum-
free adherent and suspension cultures. Glia 55, 385–399.
Ni, H.T., Hu, S., Sheng, W.S., Olson, J.M., Cheeran, M.C., Chan, A.S.,
Lokensgard, J.R., Peterson, P.K., 2004. High-level expression of
functional chemokine receptor CXCR4 on human neural
precursor cells. Brain Res. Dev. Brain Res. 152, 159–169.Panchision, D.M., Chen, H.L., Pistollato, F., Papini, D., Ni, H.T.,
Hawley, T.S., 2007. Optimized flow cytometric analysis of central
nervous system tissue reveals novel functional relationships
among cells expressing CD133, CD15, and CD24. Stem Cells 25,
1560–1570.
Peng, H., Kolb, R., Kennedy, J.E., Zheng, J., 2007. Differential
expression of CXCL12 and CXCR4 during human fetal neural
progenitor cell differentiation. J. Neuroimmune Pharmacol. 2,
251–258.
Piao, J.H., Odeberg, J., Samuelsson, E.B., Kjaeldgaard, A., Falci, S.,
Seiger, A., Sundstrom, E., Akesson, E., 2006. Cellular composi-
tion of long-term human spinal cord- and forebrain-derived
neurosphere cultures. J. Neurosci. Res. 84, 471–482.
Pruszak, J., Sonntag, K.C., Aung, M.H., Sanchez-Pernaute, R.,
Isacson, O., 2007. Markers and methods for cell sorting of human
embryonic stem cell-derived neural cell populations. Stem Cells
25, 2257–2268.
Reubinoff, B.E., Itsykson, P., Turetsky, T., Pera, M.F., Reinhartz, E.,
Itzik, A., Ben-Hur, T., 2001. Neural progenitors from human
embryonic stem cells. Nat. Biotechnol. 19, 1134–1140.
Reubinoff, B.E., Pera, M.F., Fong, C.Y., Trounson, A., Bongso, A.,
2000. Embryonic stem cell lines from human blastocysts: somatic
differentiation in vitro. Nat. Biotechnol. 18, 399–404.
Schmelzer, E., Wauthier, E., Reid, L.M., 2006. The phenotypes of
pluripotent human hepatic progenitors. Stem Cells 24,
1852–1858.
Schwartz, P.H., Bryant, P.J., Fuja, T.J., Su, H., O'Dowd, D.K., Klassen,
H., 2003. Isolation and characterization of neural progenitor cells
from post-mortem human cortex. J. Neurosci. Res. 74, 838–851.
Skottman, H., Mikkola, M., Lundin, K., Olsson, C., Strömberg, A.-M.,
Tuuri, T., Otonkoski, O., Hovatta, O., Lahesmaa, R., 2005. Gene
expression signatures of seven individual human embryonic stem
cell lines. Stem Cells 23, 1343–1356.
Studer, V., Jameson, R., Pellereau, A., Pepin, A., Chen, Y., 2004. A
microfluidic mammalian cell sorter based on fluorescence
detection. Microelectron. Eng. 73–74, 852–857.
Tamaki, S., Eckert, K., He, D., Sutton, R., Doshe, M., Jain, G.,
Tushinski, R., Reitsma, M., Harris, B., Tsukamoto, A., Gage, F.,
Weissman, I., Uchida, N., 2002. Engraftment of sorted/expanded
human central nervous system stem cells from fetal brain. J.
Neurosci. Res. 69, 976–986.
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A.,
Swiergiel, J.J., Marshall, V.S., Jones, J.M., 1998. Embryonic stem
cell lines derived fromhuman blastocysts. Science 282, 1145–1147.
Uchida, N., Buck, D.W., He, D., Reitsma, M.J., Masek, M., Phan, T.V.,
Tsukamoto, A.S., Gage, F.H., Weissman, I.L., 2000. Direct
isolation of human central nervous system stem cells. Proc.
Natl. Acad. Sci. USA 97, 14720–14725.
Ullmann, U., In't Veld, P., Gilles, C., Sermon, K., De Rycke, M., Van
de Velde, H., Van Steirteghem, A., Liebaers, I., 2007. Epithelial-
mesenchymal transition process in human embryonic stem cells
cultured in feeder-free conditions. Mol. Hum. Reprod. 13, 21–32.
Xu, C., Inokuma, M.S., Denham, J., Golds, K., Kundu, P., Gold, J.D.,
Carpenter, M.K., 2001. Feeder-free growth of undifferentiated
human embryonic stem cells. Nat. Biotechnol. 19, 971–974.
Yin, A.H., Miraglia, S., Zanjani, E.D., Almeida-Porada, G., Ogawa,
M., Leary, A.G., Olweus, J., Kearney, J., Buck, D.W., 1997.
AC133, a novel marker for human hematopoietic stem and
progenitor cells. Blood 90, 5002–5012.
Zambidis, E.T., Peault, B., Park, T.S., Bunz, F., Civin, C.I., 2005.
Hematopoietic differentiation of human embryonic stem cells
progresses through sequential hematoendothelial, primitive, and
definitive stages resembling human yolk sac development. Blood
106, 860–870.
Zhang, S.C., Wernig, M., Duncan, I.D., Brustle, O., Thomson, J.A.,
2001. In vitro differentiation of transplantable neural precursors
from human embryonic stem cells. Nat. Biotechnol. 19,
1129–1133.
